Breast cancer

Obstetrics and Gynecology

Volumn 104, Issue 4 SUPPL., 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BREAST TUMOR; ESTROGEN THERAPY; FEMALE; HUMAN; PRACTICE GUIDELINE; REVIEW;

BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PRACTICE GUIDELINES;

EID: 16544376687     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000138803.56286.6d     Document Type: Article

References (41)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A., Samuels A, Ward E, et al American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29. (Level III)
2. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-7. (Level III)
3. Hulka BS. Epidemiologic analysis of breast and gynecologic cancers. Prog Clin Biol Res 1997; 396: 17-29. (Level III)
4. Paffenbarger RS Jr., Kampert JB, Chang HG Characteristics that predict risk of breast cancer before and after menopause. Am J Epidemiol 1980; 112: 258-68. (Level II-2) (Pubitemid 10018964)
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33. (Level I) (Pubitemid 34761611)
6. Anderson GL, Limacher M, Assaf A.R., Bassford T., Beresford SA, Black H, et al Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. The Women's Health Initiative Steering Committee. JAMA 2004; 291: 1701-12. (Level I) (Pubitemid 38489892)
7. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer [published erratum appears in Lancet 1997; 350: 1484]. Lancet 1997; 350: 1047-59. (Metaanalysis)
8. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomol-gus macaques. Am J Obstet Gynecol 1996; 174: 93-100. (Level I) (Pubitemid 26037695)
9. Khan SA, Rogers MA, Obando J.A., Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 1994; 54: 993-7. (Level II-2)
10. Arpels JC, Nachtigall RD Gonadal hormones and breast cancer risk: the estrogen window hypothesis revisited. Menopause 1994; 1: 49-55. (Level III)
11. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606-16. (Metaanalysis)
12. Verheul HA, Coelingh-Bennink HJ, Kenemans P., Atsma WJ, Burger CW, Eden JA, et al Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas 2000; 36: 1-17. (Level III)
13. Lupulescu A. Estrogen use and cancer incidence: a review. Cancer Invest 1995; 13: 287-95. (Level III)
14. Pike MC, Spicer DV, Dahmoush L, Press MF Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15: 17-35. (Level III) (Pubitemid 23269068)
15. Preston-Martin S., Pike MC, Ross R.K., Jones PA, Henderson BE Increased cell division as a cause of human cancer. Cancer Res 1990; 50: 7415-21. (Level III)
16. Nelson HD, Humphrey LL, LeBlanc E, Miller J., Takano L, Chan BK, et al Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions: summary of the evidence for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality; 2002. AHRQpublication no. 03-513B. Available at: http://www.ahcpr.gov/clinic/ 3rduspstf/hrt/hrtsumm.pdf. Retrieved November 5, 2003. (Level III)
17. Li CI, Malone KE, Porter P.L., Weiss NS, Tang MT, Cushing-Haugen KL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003; 289: 3254-63. (Level II-2) (Pubitemid 37430078)
18. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Million Women Study Collaborators. Lancet 2003; 362: 419-27. (Level II-2) (Pubitemid 36999703)
19. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt L.F., Simon MS, Daling JR, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002; 100: 1148-58. (LevelII-2) (Pubitemid 35449180)
20. Chlebowski RT, Hendrix SL, Langer R.D., Stefanick ML, Gass M, Lane D, et al Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289: 3243-53. (Level I) (Pubitemid 37430077)
21. Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 2002; 186: 325-34. (Level III) (Pubitemid 34165456)
22. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/ Progestin Replacement Study follow-up (HERS II) JAMA 2002; 288: 58-66. (LevelII-1)
23. Viscoli CM, Brass LM, Kernan W.N., Sarrel PM, Suissa S, Horwitz RI A clinical trial of estrogen-replacement therapy after ischemic stroke. N EnglJ Med 2001; 345: 1243-9. (Level I) (Pubitemid 34951488)
24. Schairer C, Lubin J, Troisi S., Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [published erratum appears in JAMA 2000; 284: 2597]. JAMA 2000; 283: 485-91. (Level II-2) (Pubitemid 30062864)
25. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. AmJ Epidemiol 2000; 152: 950-64. (Level II-2)
26. Ross RK, Paganini-Hill A, Wan P.C., Pike MC Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328-32. (Level II-2) (Pubitemid 30117736)
27. Riggs BL, Hartmann LC Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice [published erratum appears in N Engl J Med 2003; 348: 1192]. N EnglJ Med 2003; 348: 618-29. (Level III) (Pubitemid 36210865)
28. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351: 1451-67. (Metaanalysis)
29. Cuzick J, Powles T, Veronesi U., Forbes J, Edwards R, Ashley S., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300. (Meta-analysis) (Pubitemid 36126189)
30. Cauley JA, Norton L, Lippman M.E., Eckert S., Krueger KA, Purdie DW, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation [published erratum appears in Breast Cancer Res Treat 2001; 67: 191]. Breast Cancer Res Treat 2001; 65: 125-34. (Level I) (Pubitemid 32193616)
31. Chlebowski RT, Col N, Winer E.P., Collyar DE, Cum mings SP, Vogel VG 3rd, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002; 20: 3328-43. (Level III) (Pubitemid 34831530)
32. Col NF, Hirota LK, Orr R.K., Erban JK, Wong JB, Lau J. Hormone replacement after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001; 19: 2357-63. (Meta-analysis) (Pubitemid 32372327)
33. Holmberg L, Anderson H; HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 2004; 363: 453-5. (Level I) (Pubitemid 38210063)
34. DiSaia PJ, Brewster WR, Ziogas A, Anton-Culver H. Breast cancer survival and hormone replacement therapy: a cohort analysis. Am J Clin Oncol 2000; 23: 541-5. (Level II-2) (Pubitemid 32429096)
35. Peters GN, Fodera T, Sabol J., Jones S, Euhus D. Estrogen replacement therapy after breast cancer: a 12-year follow-up. Ann Surg Oncol 2001; 8: 828-32. (Level II-2) (Pubitemid 34003333)
36. Natrajan PK, Gambrell RD Jr. Estrogen replacement therapy in patients with early breast cancer. Am J Obstet Gynecol 2002; 187: 289-94; discussion 294-5. (Level II-2)
37. O'Meara E.S., Rossing MA, Daling J.R., Elmore JG, Barlow WE, Weiss NS Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001; 93: 754-62. (Level II-2) (Pubitemid 32514798)
38. Vassilopoulou-Sellin R., Cohen DS, Hortobagyi G.N., Klein MJ, McNeese M, Singletary SE, et al Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 2002; 95: 1817-26. (Level II-1) (Pubitemid 35222159)
39. Marttunen MB, Hietanen P, Pyrhonen S., Tiitinen A, Ylikorkala O. A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy. Maturitas 2001; 39: 217-25. (Level II-2) (Pubitemid 32900551)
40. Pritchard KI, Khan H, Levine M; Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. CMAJ 2002; 166: 1017-22. (Level III) (Pubitemid 34304644)
41. Loprinzi CL, Kugler JW, Sloan J.A., Mailliard JA, LaVasseur BI, Barton DL, et al Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000; 356: 2059-63. (Level I) (Pubitemid 32009821)